Health

New Federal Bill Aims to Establish VA Office of Novel Therapeutics

The Veterans Health Administration Novel Therapeutics Preparedness Act is the fourth psychedelics-related bill filed in Congress this term as related legislation gains momentum.

Authors of Largest Microdosing Study Suggest Benefits Limited To Dosing Day

Recent research surveying 1,435 microdosers suggests that microdosing’s duration of effect might be more like that of drinking a coffee, with benefits that come and go by day’s end.

New RAND Report Shows Therapeutic Use Driving U.S. Views Towards Psychedelics

A new report from the RAND Corporation shows that nearly one-quarter of U.S. adults now support the legal use of psilocybin with public support driven by approval for therapeutic not personal access or recreational use.

New Theories and Findings From The Frontier of Ibogaine Research 

After publishing a new study investigating synthetic analogs for iboga molecules, scientist and co-founder of Gilgamesh Pharmaceuticals, Dalibor Sames, decided to take the compound he has described as an intelligent molecular machine.

Partners Announced for Texas Ibogaine Research Consortium Funding

The Texas Health and Human Services Commission (HHSC) has announced $50 million in awards to a collective of public universities across the state to establish the Texas Ibogaine Research Consortium.

From Nepal to Podcasts: The Viral Rise of Hallucinogenic “Mad Honey”

For millennia, Himalayan tribes have scaled cliffs to obtain psychoactive honey for its medicinal properties. However, in recent years, their sacred gift has been appropriated by thrill-seekers influenced by “podcast bros”, creating health and ecological complications.

New Mexico to Accelerate Its Launch of Therapeutic Psilocybin Access

New Mexico health officials announced plans to launch the state’s medical psilocybin therapy program by the end of December 2026 – a full year ahead of the legislative deadline.

Freedom To Heal Act Gathers Support

Supporters of the Freedom To Heal Act met with members of Congress and their staff this week seeking backing for legislation that would allow DEA-regulated medical use of Schedule I substances for patients with life-threatening conditions.

Minnesota Psychedelic Medicine Task Force Makes Recommendations

Thanks to organizing from local advocacy organizations, Minnesota has quietly become a hotbed of reform launching a psychedelic task force and deprioritized arrests related to entheogenic plants and fungi.

2025: The Year of Ibogaine Therapy

The future of ibogaine therapy was a central topic at the 2025 Psychedelic Science conference, where it was endorsed by former Texas governor Rick Perry and others. Other states are following suit, but some advocates worry about possible exploitation of the plant medicine.